Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:BEEM NASDAQ:CRSP NASDAQ:ON NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$27.11+3.0%$27.51$15.35▼$36.44$2.71B2.262.25 million shs2.14 million shsBEEMBeam Global$1.42+1.4%$1.60$1.33▼$4.04$31.08M1.48970,867 shs491,328 shsCRSPCRISPR Therapeutics$48.55+2.0%$50.93$35.38▼$78.48$4.59B1.741.81 million shs1.72 million shsONonsemi$110.21+4.0%$80.00$40.62▼$119.10$41.55B1.9413.94 million shs9.81 million shsVRTXVertex Pharmaceuticals$430.44-0.9%$444.02$362.50▼$507.92$110.23B0.31.14 million shs1.78 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+2.98%-14.88%-13.08%-2.76%+52.73%BEEMBeam Global+1.43%-23.24%-7.79%-5.33%-13.94%CRSPCRISPR Therapeutics+2.02%-7.96%-15.84%-11.15%+23.69%ONonsemi+3.95%-4.75%+28.81%+61.86%+149.01%VRTXVertex Pharmaceuticals-0.89%-4.99%-1.99%-8.27%-3.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$27.11+3.0%$27.51$15.35▼$36.44$2.71B2.262.25 million shs2.14 million shsBEEMBeam Global$1.42+1.4%$1.60$1.33▼$4.04$31.08M1.48970,867 shs491,328 shsCRSPCRISPR Therapeutics$48.55+2.0%$50.93$35.38▼$78.48$4.59B1.741.81 million shs1.72 million shsONonsemi$110.21+4.0%$80.00$40.62▼$119.10$41.55B1.9413.94 million shs9.81 million shsVRTXVertex Pharmaceuticals$430.44-0.9%$444.02$362.50▼$507.92$110.23B0.31.14 million shs1.78 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+2.98%-14.88%-13.08%-2.76%+52.73%BEEMBeam Global+1.43%-23.24%-7.79%-5.33%-13.94%CRSPCRISPR Therapeutics+2.02%-7.96%-15.84%-11.15%+23.69%ONonsemi+3.95%-4.75%+28.81%+61.86%+149.01%VRTXVertex Pharmaceuticals-0.89%-4.99%-1.99%-8.27%-3.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 2.71Moderate Buy$46.8372.75% UpsideBEEMBeam Global 1.67ReduceN/AN/ACRSPCRISPR Therapeutics 2.53Moderate Buy$65.4734.85% UpsideONonsemi 2.48Hold$89.19-19.07% DownsideVRTXVertex Pharmaceuticals 2.88Moderate Buy$555.1728.98% UpsideCurrent Analyst Ratings BreakdownLatest BEEM, VRTX, CRSP, BEAM, and ON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026ONonsemi MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$120.00 ➝ $130.005/18/2026VRTXVertex Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)5/18/2026BEEMBeam Global Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2026CRSPCRISPR Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$50.00 ➝ $56.005/13/2026BEAMBeam Therapeutics Tudor PickeringSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$39.005/13/2026BEAMBeam Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $39.005/13/2026ONonsemi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$95.00 ➝ $100.005/11/2026CRSPCRISPR Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$76.005/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $82.005/6/2026ONonsemi CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$68.00 ➝ $100.005/6/2026VRTXVertex Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$607.00 ➝ $615.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$139.74M19.96N/AN/A$11.32 per share2.39BEEMBeam Global$28.24M1.12N/AN/A$0.97 per share1.46CRSPCRISPR Therapeutics$3.51M1,334.09N/AN/A$18.81 per share2.58ONonsemi$6.00B7.20$4.30 per share25.64$18.68 per share5.90VRTXVertex Pharmaceuticals$12.22B8.94$17.42 per share24.71$76.29 per share5.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)BEEMBeam Global-$27M-$0.96N/AN/AN/A-73.22%-73.50%-42.14%N/ACRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)ONonsemi$121M$1.4178.1625.280.949.46%12.79%7.80%8/3/2026 (Estimated)VRTXVertex Pharmaceuticals$3.95B$16.8625.5322.631.8635.51%23.86%17.13%8/3/2026 (Estimated)Latest BEEM, VRTX, CRSP, BEAM, and ON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BEEMBeam Global-$0.18-$0.33-$0.15-$0.33$7.33 million$3.13 million5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million5/4/2026Q1 2026ONonsemi$0.6130$0.64+$0.0270-$0.08$1.49 billion$1.51 billion5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billion4/9/2026Q4 2025BEEMBeam Global-$0.1950-$0.07+$0.1250-$0.07$6.17 million$9.05 million3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million2/24/2026Q4 2025BEAMBeam Therapeutics-$1.13$2.33+$3.46$2.33$13.22 million$114.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/ABEEMBeam GlobalN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AONonsemiN/AN/AN/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam Therapeutics0.0916.9916.99BEEMBeam Global0.011.470.93CRSPCRISPR Therapeutics0.3217.9717.96ONonsemi0.414.873.14VRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%BEEMBeam Global26.59%CRSPCRISPR Therapeutics69.20%ONonsemi97.70%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.80%BEEMBeam Global5.57%CRSPCRISPR Therapeutics4.30%ONonsemi0.35%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableBEEMBeam Global9022.20 million20.97 millionOptionableCRSPCRISPR Therapeutics46096.45 million92.30 millionOptionableONonsemi22,670391.90 million390.53 millionOptionableVRTXVertex Pharmaceuticals6,400253.81 million253.30 millionOptionableBEEM, VRTX, CRSP, BEAM, and ON HeadlinesRecent News About These CompaniesLeonteq Securities AG Takes Position in Vertex Pharmaceuticals Incorporated $VRTX1 hour ago | marketbeat.com31,281 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A.May 20 at 3:54 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Stake Raised by Atle Fund Management ABMay 20 at 3:10 AM | marketbeat.comVertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 5:01 PM | seekingalpha.comVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItMay 19 at 3:16 PM | finance.yahoo.comVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItMay 19 at 10:01 AM | zacks.comVertex Pharmaceuticals Incorporated $VRTX Holdings Decreased by Tredje AP fondenMay 19 at 6:52 AM | marketbeat.comResona Asset Management Co. Ltd. Has $40.63 Million Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:43 AM | marketbeat.comProfund Advisors LLC Purchases 2,423 Shares of Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:18 AM | marketbeat.comProShare Advisors LLC Grows Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:18 AM | marketbeat.comAMF Tjanstepension AB Buys 83,487 Shares of Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 3:11 AM | marketbeat.comVertex Steps Into Autoimmune Care: Mid-Stage Myasthenia Gravis Trial Shows Growing Pipeline AmbitionMay 18 at 12:50 PM | tipranks.comNorth Dakota State Investment Board Buys Shares of 8,821 Vertex Pharmaceuticals Incorporated $VRTXMay 18 at 5:49 AM | marketbeat.comCanada Post Corp Registered Pension Plan Has $2.94 Million Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 18 at 3:57 AM | marketbeat.comFY2026 Earnings Estimate for VRTX Issued By Erste Group BankMay 18 at 1:23 AM | marketbeat.comLeuthold Group LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTXMay 17, 2026 | marketbeat.comSTF Management LP Lowers Position in Vertex Pharmaceuticals Incorporated $VRTXMay 17, 2026 | marketbeat.comInsider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Sells $3,144,600.00 in StockMay 17, 2026 | americanbankingnews.comVertex Pharmaceuticals Incorporated $VRTX Shares Purchased by DNB Asset Management ASMay 16, 2026 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by AnalystsMay 16, 2026 | marketbeat.comAllworth Financial LP Has $6.36 Million Position in Vertex Pharmaceuticals Incorporated $VRTXMay 16, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Manic Monday.com: The Rally Is Just the Beginning for this SaaS LeaderBy Thomas Hughes | May 11, 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableBy Thomas Hughes | May 5, 20263 Ways to Target the Resources Powering AI and Data CentersBy Nathan Reiff | May 10, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026BEEM, VRTX, CRSP, BEAM, and ON Company DescriptionsBeam Therapeutics NASDAQ:BEAM$27.11 +0.78 (+2.96%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$27.18 +0.07 (+0.24%) As of 07:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Beam Global NASDAQ:BEEM$1.42 +0.02 (+1.43%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$1.39 -0.03 (-1.97%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Global, a clean-technology innovation company, engages in the design, development, engineering, manufacture, and sale of renewably energized infrastructure products and battery solutions. Its product portfolio includes EV ARC (electric vehicle autonomous renewable charger), an infrastructure product that uses integrated solar power and battery storage to provide a mounting asset and a source of power for factory installed electric vehicle charging stations; Solar Tree DCFC, an off-grid, renewably energized, and single-column mounted smart generation and energy storage system to provide a 150kW DC fast charge to one or more electric vehicles, such as electric buses, heavy-duty vehicles, agricultural equipment, public transportation, and electric vehicles used in the construction industry; and EV ARC DCFC, a DC fast charging system for charging EVs. The company is also involved in the development of EV-Standard, a lamp standard, EV charging, and emergency power product that uses an existing streetlamp's foundation and a combination of solar, wind, grid connection, and onboard energy storage to provide curbside charging; and UAV ARC, an off-grid and renewably energized product and network used to charge aerial drone (UAV) fleets. It offers its solutions for electric vehicle (EV) charging infrastructure, energy storage, energy security, disaster preparedness, street lighting, telecommunications, energy infrastructure, and outdoor media and branding industries. The company was formerly known as Envision Solar International, Inc. and changed its name to Beam Global in September 2020. Beam Global was incorporated in 2006 and is headquartered in San Diego, California.CRISPR Therapeutics NASDAQ:CRSP$48.55 +0.96 (+2.02%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$48.50 -0.05 (-0.10%) As of 07:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.onsemi NASDAQ:ON$110.21 +4.19 (+3.95%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$108.94 -1.27 (-1.15%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.onsemi is engaged in disruptive innovations and also a supplier of power and analog semiconductors. The firm offers vehicle electrification and safety, sustainable energy grids, industrial automation, and 5G and cloud infrastructure, with a focus on automotive and industrial end-markets. It operates through the following segments: Power Solutions Group, Advanced Solutions Group, and Intelligent Sensing Group. The Power Solutions Group segment offers discrete, module, and semiconductor products that perform multiple application functions, including power switching, power conversion, signal conditioning, circuit protection, signal amplification, and voltage reference functions. The Advanced Solutions Group segment is involved in the designing and developing of analog, mixed-signal, advanced logic, ASSPs and ASICs, Wi-Fi and power solutions for a broad base of end-users in the automotive, consumer, computing, industrial, communications, medical and aerospace/defense markets. The Intelligent Sensing Group segment is focused on the designing and developing of CMOS and CCD image sensors, as well as proximity sensors, image signal processors, single photon detectors, incluVertex Pharmaceuticals NASDAQ:VRTX$430.44 -3.87 (-0.89%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$429.50 -0.94 (-0.22%) As of 07:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
